Final answer:
The primary cardiovascular side effect of bevacizumab is an increased risk of stroke or heart attack. Bevacizumab use also correlates with a risk of developing blood clots.
Step-by-step explanation:
The primary cardiovascular side effect of bevacizumab, a medication often used in the treatment of various cancers, is an increased risk of stroke or heart attack. This medication can also lead to blood clots, a serious concern for patients being treated with this agent. It is important for individuals receiving bevacizumab to be closely monitored for any signs or symptoms of cardiovascular complications. Bevacizumab is a monoclonal antibody that inhibits the vascular endothelial growth factor (VEGF). It is commonly used in cancer treatment, particularly for certain types of advanced cancers, including colorectal, lung, breast, kidney, and ovarian cancers.